about
KASL clinical practice guidelines: management of chronic hepatitis BAcute exacerbation of chronic hepatitis B: the dilemma of differentiation from acute viral hepatitis BFuture Therapy for Hepatitis B Virus: Role of ImmunomodulatorsCurrent role of transient elastography in the management of chronic hepatitis B patientsThe effect of human immunodeficiency virus on hepatitis B virus serologic status in co-infected adults.Association of human leukocyte antigen DQB1 and DRB1 alleles with chronic hepatitis B.Hepatitis B virus management to prevent reactivation after chemotherapy: a review.Designing immune therapy for chronic hepatitis B.Interleukin-21 responses in patients with chronic hepatitis B.Low rates of hepatitis B virus screening at the onset of chemotherapy.KASL Clinical Practice Guidelines: Management of chronic hepatitis B.Evaluation of Interleukin-10 Levels in Patients Diagnosed with Chronic HepatitisHepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapyOverexpression of Fc receptor-like 1 associated with B-cell activation during hepatitis B virus infectionThe role of tumour necrosis factor in hepatitis B infection: Jekyll and Hyde.Non-antigen-specific and antigen-specific immune therapies for chronic hepatitis B: evidences from laboratory benches and patient's bedsides.Exploring the Therapeutic Potentials of iNKT Cells for Anti-HBV Treatment.Immune balance in Hepatitis B Infection: Present and Future Therapies.miR146a impairs the IFN-induced anti-HBV immune response by downregulating STAT1 in hepatocytes.Alanine aminotransferase levels are not significantly elevated in patients with HIV/HBV co-infection and lamivudine resistance.Immunosuppression in Patients with Chronic Hepatitis B.Modeling the adaptive immune response in HBV infection.Development of chronic hepatitis B virus infection in hepatitis B surface antigen negative HIV/HBV co-infected adults: a rare opportunistic illness.
P2860
Q26752475-3FDDA124-3632-4904-A211-1E8A22A3E6C0Q27022622-1C915DD0-C501-4BC8-A7A0-C7DA92EF56C2Q28078148-B7EC052E-C473-4F0A-A0F8-1CFC73DBFA31Q30358894-00D06DBB-8F6E-44AF-8F59-C31837F6BB67Q33525046-195E3B05-63D1-45A4-841E-AB818CD6C6DCQ33845532-F82975E6-C1FE-4FBD-8FB1-EC9412E8DF27Q34397738-4F4E5DF7-F3EE-4221-B17C-037A229AD294Q34825732-78702E9B-9DC0-47DB-B362-FF128EC40261Q35034678-CEEA69CC-9AF6-4366-B1CB-C1F2771E646DQ36095262-497C9F7A-8E0E-4BCE-9A32-09A48DAFBBDCQ36153966-393118E1-572A-42C9-95D7-E962F906823DQ36418044-F564655F-AAA3-49A5-B553-3822B39C8155Q37076886-E9E1A728-EB1D-4367-89D9-A60D3CB6954EQ37371002-792859AC-A1AA-4860-965F-CFA775147260Q37538505-8A1089F1-586B-4344-86AB-85B3241A3415Q38098583-27BC047D-24AF-4A29-B6E5-6A08A7A882B1Q38273315-B5257033-B835-48CF-B2F4-A969460500D7Q38733622-D837BDCE-ECFB-49DC-8BCA-8A126D37DBC9Q42281174-B95AF480-ADBF-4B6D-9ADE-62DF1678F06DQ42598604-4934148A-4DBF-4554-88B3-C8194A5E5283Q42764680-58E8FA40-61C2-4F3F-B684-79D5EBDF67C2Q45253427-832D0779-63BB-49C8-9E5B-3D20CC273B9EQ45365130-F1283BF5-6DB8-4DC3-A34E-59557F7093C7
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
The immunology of hepatitis B.
@ast
The immunology of hepatitis B.
@en
The immunology of hepatitis B.
@nl
type
label
The immunology of hepatitis B.
@ast
The immunology of hepatitis B.
@en
The immunology of hepatitis B.
@nl
prefLabel
The immunology of hepatitis B.
@ast
The immunology of hepatitis B.
@en
The immunology of hepatitis B.
@nl
P1476
The immunology of hepatitis B.
@en
P2093
John M Vierling
P304
727-59, vii-viii
P356
10.1016/J.CLD.2007.08.001
P577
2007-11-01T00:00:00Z